Veracyte, Inc. Veracyte, Inc.

Veracyte, Inc.

VCYT

Classificação em ações #4345
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Preço da ação
$45.36
Valor de mercado
$3.65B
Variação (1 dia)
1.27%
Variação (1 ano)
25.65%
País
US
Negociar Veracyte, Inc. (VCYT)

Categoria

Healthcare
Receita da Veracyte, Inc. (VCYT)
Receita em Jun 2026 TTM: $561.90M
De acordo com os últimos relatórios financeiros da Veracyte, Inc., a receita atual da empresa (TTM) é $561.90M. Em 2023, a empresa obteve uma receita de $361.05M um aumento em relação a a receita do ano 2022, que foi de $296.54M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Veracyte, Inc. de 2011 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) $561.90M 26.05%
2024 $445.76M 23.46%
2023 $361.05M 21.76%
2022 $296.54M 35.09%
2021 $219.51M 86.85%
2020 $117.48M -2.40%
2019 $120.37M 30.82%
2018 $92.01M 27.87%
2017 $71.95M 10.55%
2016 $65.09M 31.48%
2015 $49.50M 29.62%
2014 $38.19M 74.51%
2013 $21.88M 88.20%
2012 $11.63M 339.62%
2011 $2.65M 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
$46.34B 8,146.31%
US
$25.11B 4,368.23%
US
$2.71B 381.77%
US
- -
CN
$7.37B 1,211.98%
US